Syneos Health has announced the acquisition of RxDataScience, a healthcare-focused data analytics, data management and artificial intelligence company.
RxDataScience’s product lifecycle solutions include scientific computing for R&D, patient journey, decentralized trials, RWE, predictive analytics and commercial market research. Additionally, RxDataScience offers a consulting-based model providing an iterative approach to develop and deliver analytics solution prototypes in six-to-eight-week sprints.
RxDataScience further scales Syneos Health’s data science abilities, adding capabilities and knowledge in data engineering and management. RxDataScience will be part of the Syneos Health Dynamic Assembly network.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.